Research at risk if ‘march-in’ rights take patents on pharmaceuticals away, say US industry groups
Pharmaceutical companies have condemned plans to allow federal agencies to effectively void patent rights if drugs are deemed too costly.
Last week the White House released draft guidance on the use of ‘Bayh-Dole’ or ‘march-in’ rights, which allow exclusive patents to be taken away for federally funded research when drug companies are not charging a reasonable price.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.